FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382502616> ?p ?o ?g. }

• W4382502616 endingPage "729" @default.
• W4382502616 startingPage "723" @default.
• W4382502616 abstract "In the adjuvant treatment of low-risk stage-III colon cancer treated surgically, 3 months of CAPOX followed by 3 months of capecitabine is not a common clinical practice. Since there are no data on this practice in the literature, we have no idea how often it is used. However, it should be noted that this application is used in some centers due to the cumulative neurotoxicity of oxaliplatin but there are insufficient data in the literature on its efficacy.The data of patients with colon cancer treated surgically who were followed up in 12 different oncology centers in Turkey between November 2004 and June 2022 were analyzed retrospectively.The study included 194 patients. The treatment arms were as follows: 3 months of CAPOX followed by 3 months of capecitabine = arm A and CAPOX/FOLFOX (6 months) = arm B. There were 78 patients (40.2%) in arm A and 116 patients (59.8%) in arm B. The median age and sex distribution were similar between the treatment arms. The median follow-up period of all patients was 34.4 months (95% CI, 29.1-39.7). When arm A was compared with arm B, 3-year disease-free survival (DFS) was 75.3% vs. 88.4% and 5-year DFS was 75.3% vs. 82.8%, respectively. There were similar DFS outcomes between the treatment arms (p=0.09). Rates of any grade of neuropathy were numerically lower in arm A, but the difference between the treatment arms was not statistically significant (51.3% vs. 56.9%; p=0.44). The frequency of neutropenia was similar between the treatment arms.In this study, the efficacy and safety of the 3 months of CAPOX followed by 3 months of capecitabine chemotherapy regimen in the adjuvant treatment of low-risk stage-III colon cancer treated surgically was proven. This result may also support the discontinuation of oxaliplatin at 3 months while continuing fluoropyrimidines, which is a common clinical practice but lacks sufficient data." @default.
• W4382502616 created "2023-06-30" @default.
• W4382502616 creator A5000010091 @default.
• W4382502616 creator A5001274420 @default.
• W4382502616 creator A5005309444 @default.
• W4382502616 creator A5015745342 @default.
• W4382502616 creator A5018689758 @default.
• W4382502616 creator A5020836701 @default.
• W4382502616 creator A5035460759 @default.
• W4382502616 creator A5041705584 @default.
• W4382502616 creator A5045770109 @default.
• W4382502616 creator A5046906810 @default.
• W4382502616 creator A5052112651 @default.
• W4382502616 creator A5052712567 @default.
• W4382502616 creator A5055369408 @default.
• W4382502616 creator A5067518254 @default.
• W4382502616 creator A5077016956 @default.
• W4382502616 creator A5084060158 @default.
• W4382502616 creator A5088599329 @default.
• W4382502616 creator A5088799414 @default.
• W4382502616 creator A5076528335 @default.
• W4382502616 date "2023-01-01" @default.
• W4382502616 modified "2023-10-18" @default.
• W4382502616 title "Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically" @default.
• W4382502616 cites W1529818185 @default.
• W4382502616 cites W1960485012 @default.
• W4382502616 cites W2077979472 @default.
• W4382502616 cites W2118950501 @default.
• W4382502616 cites W2138985803 @default.
• W4382502616 cites W2144495943 @default.
• W4382502616 cites W2171232394 @default.
• W4382502616 cites W2260992463 @default.
• W4382502616 cites W2313857605 @default.
• W4382502616 cites W2935820515 @default.
• W4382502616 cites W3110292103 @default.
• W4382502616 doi "https://doi.org/10.1159/000531722" @default.
• W4382502616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37379817" @default.
• W4382502616 hasPublicationYear "2023" @default.
• W4382502616 type Work @default.
• W4382502616 citedByCount "0" @default.
• W4382502616 crossrefType "journal-article" @default.
• W4382502616 hasAuthorship W4382502616A5000010091 @default.
• W4382502616 hasAuthorship W4382502616A5001274420 @default.
• W4382502616 hasAuthorship W4382502616A5005309444 @default.
• W4382502616 hasAuthorship W4382502616A5015745342 @default.
• W4382502616 hasAuthorship W4382502616A5018689758 @default.
• W4382502616 hasAuthorship W4382502616A5020836701 @default.
• W4382502616 hasAuthorship W4382502616A5035460759 @default.
• W4382502616 hasAuthorship W4382502616A5041705584 @default.
• W4382502616 hasAuthorship W4382502616A5045770109 @default.
• W4382502616 hasAuthorship W4382502616A5046906810 @default.
• W4382502616 hasAuthorship W4382502616A5052112651 @default.
• W4382502616 hasAuthorship W4382502616A5052712567 @default.
• W4382502616 hasAuthorship W4382502616A5055369408 @default.
• W4382502616 hasAuthorship W4382502616A5067518254 @default.
• W4382502616 hasAuthorship W4382502616A5076528335 @default.
• W4382502616 hasAuthorship W4382502616A5077016956 @default.
• W4382502616 hasAuthorship W4382502616A5084060158 @default.
• W4382502616 hasAuthorship W4382502616A5088599329 @default.
• W4382502616 hasAuthorship W4382502616A5088799414 @default.
• W4382502616 hasConcept C121608353 @default.
• W4382502616 hasConcept C126322002 @default.
• W4382502616 hasConcept C141071460 @default.
• W4382502616 hasConcept C146357865 @default.
• W4382502616 hasConcept C151730666 @default.
• W4382502616 hasConcept C2777909004 @default.
• W4382502616 hasConcept C2778260052 @default.
• W4382502616 hasConcept C2780962732 @default.
• W4382502616 hasConcept C526805850 @default.
• W4382502616 hasConcept C71924100 @default.
• W4382502616 hasConcept C86803240 @default.
• W4382502616 hasConceptScore W4382502616C121608353 @default.
• W4382502616 hasConceptScore W4382502616C126322002 @default.
• W4382502616 hasConceptScore W4382502616C141071460 @default.
• W4382502616 hasConceptScore W4382502616C146357865 @default.
• W4382502616 hasConceptScore W4382502616C151730666 @default.
• W4382502616 hasConceptScore W4382502616C2777909004 @default.
• W4382502616 hasConceptScore W4382502616C2778260052 @default.
• W4382502616 hasConceptScore W4382502616C2780962732 @default.
• W4382502616 hasConceptScore W4382502616C526805850 @default.
• W4382502616 hasConceptScore W4382502616C71924100 @default.
• W4382502616 hasConceptScore W4382502616C86803240 @default.
• W4382502616 hasIssue "11" @default.
• W4382502616 hasLocation W43825026161 @default.
• W4382502616 hasLocation W43825026162 @default.
• W4382502616 hasOpenAccess W4382502616 @default.
• W4382502616 hasPrimaryLocation W43825026161 @default.
• W4382502616 hasRelatedWork W2037039278 @default.
• W4382502616 hasRelatedWork W2235788479 @default.
• W4382502616 hasRelatedWork W2356910782 @default.
• W4382502616 hasRelatedWork W2361525411 @default.
• W4382502616 hasRelatedWork W2373559083 @default.
• W4382502616 hasRelatedWork W2377024980 @default.
• W4382502616 hasRelatedWork W2378173381 @default.
• W4382502616 hasRelatedWork W2809146871 @default.
• W4382502616 hasRelatedWork W3110357236 @default.
• W4382502616 hasRelatedWork W4234281245 @default.
• W4382502616 hasVolume "101" @default.

• next